You Didn’t Build a Moat. You Built a Moment.
The biotech companies that will look back at this decade with regret won’t be the ones that failed to adopt AI. They’ll be the ones that adopted it, moved fast, filed patents, and assumed the hard work was done — while their competitive window quietly closed behind them.
Speed is seductive. When AI compresses a discovery timeline from four years to eighteen months, it feels like an advantage. It is an advantage. But it’s a temporary one, and the clock on it is shorter than most commercialization timelines.
Here is the uncomfortable arithmetic: if your platform accelerated your discovery, it will accelerate your competitor’s design-around. The same computational infrastructure that let you find this molecule will help someone else find the next one. The question your IP strategy needs to answer isn’t whether you can protect what you’ve built. It’s whether the protection you have can survive the speed at which the competitive landscape is now moving.
Why the Traditional Patent Calculus Is Breaking
The dominant IP strategy in biotech has always been to file early, file broadly, and build a portfolio large enough to create friction for competitors. That approach was designed for a world where iteration was slow,, where replicating or designing around a molecule took years of laboratory work, and where broad claims could maintain their deterrent value through an entire commercialization cycle.
AI changes that timeline. Not in the future. Now. Computational workflows can map chemical space, identify structural analogs, and optimize alternative binding profiles at a speed that fundamentally alters how long a given protection strategy can hold. A claim that might have provided durable competitive insulation in a pre-AI environment may be circumvented significantly faster when a well-resourced competitor has comparable computational infrastructure.
Most companies are still calibrating their IP strategy to the old timeline. That’s a mismatch with real commercial consequences.
THE QUESTION MOST COMPANIES ASK
Can we get this patented?
THE QUESTION THAT ACTUALLY MATTERS
How long before a capable competitor can work around it and does that window cover our commercialization timeline?
The Molecule Is the Output. The Platform Is the Asset.
There is a persistent tendency in AI biotech to over-concentrate protection around the final therapeutic output. The optimized molecule gets the attention. The discovery infrastructure that generated it, the proprietary datasets, the training workflows, the optimization pipelines, the feedback systems gets comparatively little.
That’s a structural error. The molecule is the current output of the platform. A competitor who can replicate your platform can, in theory, generate the next one independently. A competitor who cannot replicate your platform is genuinely disadvantaged, regardless of what they can infer from your published claims.
Durable defensibility in AI therapeutics is increasingly platform-level, not molecule-level. That means the IP strategy needs to protect the system, its data advantages, its workflow architecture, its learning loops, not just the thing that came out of it most recently. Many portfolios look strong in isolation and weak strategically, because they’ve protected the outputs while leaving the generative infrastructure largely exposed.
Large Portfolios Are Not the Same as Strong Ones
There’s a particular illusion of safety that comes with filing volume. A portfolio with three hundred applications feels formidable. It may not be. What matters isn’t how many filings exist but whether those filings collectively create meaningful friction for the specific competitive threats you actually face.
Portfolios built for the optics of defensibility, broad filing programs designed to signal strength rather than systematically protect commercial value, tend to absorb IP budget without delivering proportionate protection. The spend is real. The insulation is not.
Sophisticated investors have started to pick this apart. They’re not impressed by application counts. They want to understand the relationship between the portfolio and the commercial pathway. They want to know which claims actually matter, which positions are genuinely held, and where the exposure sits. A company that can answer those questions cleanly is in a fundamentally different conversation than one that can only offer a filing number.
“A moat isn’t defined by whether competitors can see what you built. It’s defined by whether they can realistically reproduce the system that made it possible.”
The Compression Problem No One Is Talking About Enough
The real risk for AI biotech companies isn’t that they won’t discover good molecules. It’s that the window between discovery and meaningful competitive response will continue to compress faster than their protection strategies evolve.
Therapeutics take a long time to reach market. IP strategies need to provide protection across that entire window — including the period after competitors have had years to study your public filings, understand your approach, and direct their own AI systems at the same problem space. If the protection strategy was built for a slower competitive environment, the asset may arrive at commercialization with less insulation than the models assumed.
The companies navigating this well are thinking about IP as competitive positioning, not just legal protection. They’re building portfolios that account for AI-accelerated design-around risk. They’re protecting platform infrastructure, not just molecular outputs. They’re asking the harder question about how long their advantages will actually last, and building strategy around the honest answer rather than the optimistic one.
A moment of advantage is valuable. A moat is built over time, with discipline, around the things that are genuinely hard to replicate. Knowing which one you have is the beginning of a real IP strategy.